Oncolytics Biotech (ONCY) Operating Margin (2016 - 2017)
Oncolytics Biotech (ONCY) posted quarterly Operating Margin of 0.0% for Q2 2017, down 36832.0% year-over-year from N/an in Q2 2016, and down 100.0% quarter-over-quarter from 368.32% in Q2 2016.
Oncolytics Biotech (ONCY) Operating Margin (2016 - 2017) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Operating Margin for 2 consecutive years, with 0.0% the latest figure, recorded in Q2 2017.
- In Q2 2017, Operating Margin fell 36832.0% year-over-year to 0.0%; the TTM figure through Jun 2017 stood at 0.0% (down 185.0% YoY), while the FY2018 annual figure was 0.0%, changed N/A from the prior year.
- Operating Margin eased to 0.0% in Q2 2017 per ONCY's latest filing, from 368.32% in the prior quarter.
- Across five years, Operating Margin topped out at 368.32% in Q2 2016 and bottomed at 0.0% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.75% |
| 10 | Oncolytics Biotech | 98.14 Mn | 98.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 0.00% |
| Jun 30, 2016 | 368.32% |